[1] The Biosimilars Council and Association for Accessible Medicines, 2017, The New Frontier for Improved Access to Medicines: Biosimilars & Interchangeable Biologic Products.
[2] IQVIA MIDAS MAT, Q4 2017
[3] Mulcahy, Hlavka, & Case, 2017, Biosimilar Cost Savings in the United States, RAND Corporation.
[4] Deloitte, 2016, Winning with Biosimilars. Opportunities in Global Markets.
[5] CSIRO, 2017, Medical Technologies and Pharmaceuticals: A Roadmap for unlocking future growth opportunities for Australia.
[6] U.S. Food & Drug Administration, 2018, Biological Product Definitions.
[8] Blackstone & Fuhr Joseph Jr, 2013, The Economics of Biosimilars, American Health & Drug Benefits, 6(8): 469-478
[9] EvaluatePharma, 2017, World Preview 2017, Outlook to 2022, 10th Edition.
[10] AbbVie, 2017, AbbVie Reports Third-Quarter 2017 Financial Results, available at http://investors.abbvie.com
[11] Abrahao-Machado & Scapulatempo-Neto, 2016, HER2 Testing in Gastric Cancer: An Update, World Journal of Gastroenterology, 22(19)
[12] Metastatic Breast Cancer Network, Incidence and Incidence Rates, mbcn.org [accessed: April 2018]
[13] World Health Organization: International Agency for Research on Cancer, GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012
[14] World Health Organization, 2016, Global Report on Psoriasis.
[15] Rachakonda T, Schupp C, & Armstrong A, 2014, Psoriasis Prevalence Among Adults in the United States, Journal of the American Academy of Dermatology, 70(3).
[16] Cross et al., 2014, The Global Burden of Rheumatoid Arthritis: Estimates from the Global Burden of Disease 2010 Study, Annals of the rheumatic diseases, 73(7)
[17] Crohn’s & Colitis Foundation, 2016, crohnscolitisfoundation.org [accessed April 2018]
[18] Simoes et al., 2015, Challenges and Opportunities in Developing Respiratory Syncytial Virus Therapeutics, The Journal of Infectious Diseases, 211(Suppl 1): S1-S20
[19] International Osteoporosis Foundation, Epidemiology, iofbonehealth.org [accessed: April 2018]
[20] EvaluatePharma, 2018, World Preview 2018, Outlook to 2024, 11th Edition.
[21] EvaluatePharma, 2019, World Preview 2019, Outlook to 2024, 12th Edition.
[22] EvaluatePharma, 2020, Cancer Immunotherapy Drug Classes to Watch in 2020 and Beyond. Available at: https://www.evaluate.com/cancer-immunotherapy-drug-classes-watch-2020-and-beyond [accessed: September 2020]
[23] World Cancer Research Fund, 2020, Skin Cancer Statistics. Available at: https://www.wcrf.org/dietandcancer/cancer-trends/skin-cancer-statistics [accessed: September 2020]
[24] World Cancer Research Fund, 2020, Lung Cancer Statistics. Available at: https://www.wcrf.org/dietandcancer/cancer-trends/lung-cancer-statistics [accessed: September 2020]